Dame Emma Walmsley has been CEO at GSK since 2017. This week has kicked off with the unexpected news that Emma Walmsley is standing down as chief executive of GSK after eight years, to be replaced by ...

Astellas has suffered another major setback with geographic atrophy (GA) treatment Izervay, this time in the US. The company has received a complete response letter (CRL) from the FDA for a proposed ...

In another major setback for abortion care in the US, a US court has issued an order restricting the distribution of ...

A digital therapy that could reduce the severity of chronic tic disorders like Tourette syndrome has been recommended for use by the NHS for the first time. The technology, known as ORBIT (Online ...

The first data has emerged on the uptake of Novo Nordisk's new oral version of GLP-1 agonist weight-loss therapy Wegovy, with encouraging signs of strong demand as a potential rival from Eli Lilly ...

US MFN rules and new tariffs are narrowing the US–ex-US price gap and drawing more manufacturing and capital investment toward the United States. Low European or UK list prices now directly affect US ...

The heart and key to success of contract research organisations (CROs) and contract development and manufacturing organisations (CDMOs) is to ensure every process and procedure is as meticulous as ...

Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 agonists for diabetes, with new data for Mounjaro on cardiovascular outcomes. The results of the SURPASS-CVOT trial showed ...

With the Federal Reserve poised to implement interest rate cuts (albeit fewer than earlier forecasts assumed) and FTC leadership turnover anticipated, there may be broader shifts in how capital is ...

Elon Musk's Neuralink has been awarded breakthrough status from the FDA for an implantable chip – dubbed Blindsight – that promises to restore the sight of people with vision impairment. There's ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Novartis has claimed a first-in-class regulatory approval in the US for oral BTK inhibitor remibrutinib as a second-line treatment for chronic spontaneous urticaria (CSU), also known as chronic hives.